Interferon alpha may drive Sjögren's disease in 60% of patients
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Interferon alpha is an inflammatory mediator that can cause Sjögren's syndrome, an autoimmune disease. This was revealed in a study carried out by University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, published in the journal Lancet Rheumatology, could make it easier in the medium term to develop drugs to fight this chronic condition.
Sjögren's syndrome (also known as Sjögren's disease) has a wide range of symptoms, from dry eyes and itchy skin to muscle and joint pain and chronic fatigue. The condition, an autoimmune disease, is in the group known as collagen disorders, which also includes lupus. With these diseases, the immune system attacks the body's own structures inside organs and connective tissue, damaging them.
Sjögren's syndrome mainly affects the exocrine glands, i.e., groups of cells that secrete water or mucus at the surface of the skin or inside the digestive tract, causing chronic inflammation and preventing them from doing their job properly.
"This is why people living with the condition complain of low saliva production as well as dryness in their eyes and mucous membranes, among other things," explains Professor Rayk Behrendt, who led the Bonn-based part of the study.
He is a researcher in the Institute of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn and a member of the Life and Health Transdisciplinary Research Area and ImmunoSensation3 Cluster of Excellence at the University of Bonn.
Is dysregulated interferon alpha the culprit?
As with other collagen disorders, other parts of the body can also be damaged over time, which is why doctors call it a "systemic disease." The actual cause of the condition is unknown.
"For a long time, however, there's been a suspicion that an inflammatory mediator, specifically interferon alpha, is dysregulated in people affected by the disease," Behrendt says. "Their bodies are producing too much of it, and this is what might be triggering the various symptoms."
However, this hypothesis had not yet been proven—all that was known was that many people with Sjögren's syndrome have an elevated level of interferon alpha. Yet many patients do not respond to treatments that weaken the effect of interferon alpha. The latest study has now provided an indication of why this is the case.
"We studied the immune system of over 170 women and men with Sjögren's disease very closely," Behrendt explains.
A highly sensitive detection method
Except when it is fighting viral infections, the body normally produces interferon alpha only in tiny quantities, so the researchers used a new, ultrasensitive method to detect individual molecules of it.
They discovered that around 60% of patients had increased levels of interferon alpha, and it was precisely this 60% that also exhibited other characteristic differences in their immune systems compared with their fellow patients. For example, the activity of certain immune genes—and thus the release of the corresponding proteins—was different.
"We also found a molecule called TRIM21 in the other 40%, which the patients with elevated interferon alpha levels didn't have," says Dr. Ivana Jorgacevic, who carried out some of the experiments.
In experiments using mice, the researchers found that these heightened levels of interferon alpha were responsible for both the characteristically altered protein signature and the absence of TRIM21. The working groups also analyzed data on nearly 50,000 people from a UK database known as the UK Biobank.
These individuals had all provided regular blood samples over many years, and around 250 of them were diagnosed with Sjögren's syndrome. Half received their diagnoses partway through this period.
"Analysis of the protein signature in the blood of these 250 patients showed that elevated interferon alpha had already been detected more than 10 years before they developed the disease," Jorgacevic explains. "Plus, they had no TRIM21."
Behrendt adds, "The combination of data from our own cohort, our analysis of the UK Biobank data and our studies on mice enabled us to demonstrate that there is a causal link between interferon alpha and characteristic changes in the immune system."
Two different types of Sjögren's syndrome
There therefore appear to be at least two different types of Sjögren's syndrome. Although they differ in terms of both the amount of interferon produced in the body and a characteristic protein signature, they are clinically indistinguishable, at least initially.
This "immune diversity" is not just of academic interest. "Now, for the first time, we can take treatments geared toward suppressing the interferon effect and trial them specifically on patients with elevated interferon levels," Behrendt says.
"We might also find new approaches to treatment that will help a large percentage of patients over the long term."
The ImmunoSensation3 Cluster of Excellence works to understand precisely these kinds of immune diversity and is therefore now also keen to investigate why interferon alpha plays a role in some patients but not others.
Publication details
Deborah Forbes et al, Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study, The Lancet Rheumatology (2026). DOI: 10.1016/s2665-9913(26)00038-x
Journal information: The Lancet Rheumatology
Clinical categories
RheumatologyAllergy and immunology Provided by University of Bonn Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Interferon alpha may drive Sjögren's disease in 60% of patients (2026, July 20) retrieved 21 July 2026 from https://medicalxpress.com/news/2026-07-interferon-alpha-sjgren-disease-patients.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.